ADOA is the most common hereditary optic atrophy disease. However, there's very little research on the disease to help those living with its many debilitating symptoms. 


There is currently no cure for Autosomal Dominant Optic Atrophy (ADOA). Since this disease deteriorates the optic nerve, visual aids such as glasses or contacts will not help improve one's vision impairment. Management generally consists of regular eye exams, including measurement of visual acuity, color vision, visual fields and optical coherence tomography (OCT). Low-vision aids in individuals with severely decreased visual acuity can be helpful. (7)


While ADOA is currently identified as untreatable there is one study that showed improved visual acuity and function with the use of Idebenone therapy.  Idebenone is a synthetic analog of coenzyme Q10. It has powerful antioxidant properties that help prevent free radical damage to our cells. It has shown to be effective for those with cardiac and mitochondrial issues. The study was conducted on seven patients with Dominant Optic Atrophy who carry the OPA1 gene mutation. Results showed, for the first time, some improvement in visual function after Idebenone therapy.  Read more about Idebenone Treatment in Patients with OPA1-mutant dominant optic atrophy.


Research on ADOA has not begun due to a lack of available funding. We are connected with the researchers who have done the most progressive studies on ADOA and we want to help them continue their work to find a therapy and cure. Currently, Stem Cell research is one of the fields of study for Autosomal Dominant Optic Atrophy. Read the articles below to learn more about Stem Cell Therapy and studies conducted on Autosomal Dominant Optic Atrophy.




Help us impact the lives of thousands of children who suffer from this rare disease.